# Dapagliflozin in Pulmonary Arterial Hypertension

> **NCT05179356** · PHASE2 · COMPLETED · sponsor: **Mads Ersbøll** · enrollment: 52 (actual)

## Conditions studied

- Pulmonary Arterial Hypertension
- Chronic Thromboembolic Pulmonary Hypertension

## Interventions

- **DRUG:** Dapagliflozin 10 MG [Farxiga]
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT05179356
- **Lead sponsor:** Mads Ersbøll
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2023-01-01
- **Primary completion:** 2026-01-13
- **Final completion:** 2026-01-13
- **Target enrollment:** 52 (ACTUAL)
- **Last updated:** 2026-01-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05179356

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05179356, "Dapagliflozin in Pulmonary Arterial Hypertension". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT05179356. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*